ストックスクリーナーアプリを入手
22.02
8.86%
-2.14
アフターアワーズ：
22.10
0.08
+0.36%
前日終値:
$24.16
開ける：
$23.95
24時間の取引高:
33.06M
Relative Volume:
1.08
時価総額：
$5.02B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
42.18
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
-11.10%
1か月 パフォーマンス:
+40.88%
6か月 パフォーマンス:
-61.92%
1年 パフォーマンス:
-33.01%
1日の値動き範囲:
$21.70
$24.25
1週間の範囲:
$21.70
$25.24
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
22.02 | 5.02B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.83 | 56.33B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.67 | 48.83B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
10.07 | 44.83B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.73 | 33.46B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
524.28 | 22.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - MSN
Hims & Hers (HIMS) soars 10.3% on analyst upgrades, new deal - MSN
Hims & Hers (HIMS) tumbles 8.86% on market bloodbath, profit-taking - MSN
Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking - Insider Monkey
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc.HIMS - Morningstar
Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile? - Yahoo Finance
Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit - Law360
Hims & Hers stock falls as technical resistance weighs and buyers lose steam near $24 - Traders Union
Hims & Hers Elevates Technology-Driven Healthcare Accessibility - MSN
Investor relations - HIMS Investor Relations
Hims & Hers Health stock: Daily momentum and support levels drive a 3.41% advance - Traders Union
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Benzinga
Buying pressure lifts Hims & Hers Health stock higher in today's trading - Traders Union
Understanding Momentum Shifts in (HIMS) - Stock Traders Daily
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
Hims & Hers Health, Inc. (HIMS) suffers a larger drop than the general market: Key insights - MSN
Insider Sell: Irene Becklund Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Hims & Hers Health Faces Another Legal Setback Amid Probes and Falling Shares - StocksToTrade
Insider Selling: Hims & Hers Health (NYSE:HIMS) COO Sells 97,289 Shares of Stock - MarketBeat
Hims & Hers Health (NYSE:HIMS) Insider Sells $136,511.01 in Stock - MarketBeat
Hims & Hers health COO Chi sells $2.4m in shares - Investing.com
Top Healthcare Stocks To Follow TodayMarch 18th - MarketBeat
Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal - Benzinga
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk - Stocktwits
Telemedicine company Hims & Hers Health Inc. (NYSE: HIMS) announced that its service platform will expand its product range to include Novo Nordisk's Wegovy® (semaglutide) oral tablets and injections, as well as Ozempic® injections. - Bitget
A New Era of Weight Management is Coming to Hims & Hers - Hims & Hers Newsroom
Greenfield Seitz Capital Management LLC Sells 43,334 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move - Yahoo Finance
Healthcare Stocks To ConsiderMarch 17th - MarketBeat
HIMS Stock: After a 57% Surge, Is It Time to Buy Hims & Hers? - CMC Markets
Hims & Hers Health shares see a dip — What is pressuring the stock - Traders Union
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Aquatic Capital Management LLC Purchases New Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - MSN
HIMS: Leerink Partners Raises Price Target to $25.00 | HIMS Stoc - GuruFocus
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $25.00 at Leerink Partners - MarketBeat
Hims And Hers Health Pushes Into Complex Care And Global Growth - Yahoo Finance
HIMS Expands Personalized Digital Healthcare Access and Services - The Globe and Mail
Hims & Hers Health Stock Slips After Surging 50% In A Month - Benzinga
Novo Nordisk & Hims & Hers: Supply Deal for Ozempic and WegovyNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
What is behind Hims & Hers Health stock's recent drop in value today - Traders Union
Why the Novo Nordisk and Hims & Hers deal is a win for both stocks - MSN
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks - Yahoo Finance
Farallon Capital Management LLC Purchases 2,533,271 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers under fire over copycat weight loss drugs - WNTZ-TV FOX 48
Hims & Hers Health (HIMS) Is Up 57.4% After Renewed Novo Nordisk GLP-1 PartnershipHas The Bull Case Changed? - simplywall.st
Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk - AD HOC NEWS
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
Clear Street Group Inc. Invests $87.37 Million in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers (HIMS) Soars 57.4% on New Deal - Insider Monkey
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
1.33%
大文字化:
|
ボリューム (24 時間):